𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐍𝐞𝐰𝐬 𝐢𝐧 𝐅𝐢𝐛𝐫𝐨𝐦𝐲𝐚𝐥𝐠𝐢𝐚 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡! Tonix Pharmaceuticals announces a major milestone: the FDA has officially accepted the New Drug Application (NDA) for TNX-102 SL, a non-opioid therapy for fibromyalgia management. This innovative treatment aims to address the needs of over 10 million adults in the U.S. affected by this chronic pain condition. With Fast Track designation and successful results from two Phase 3 clinical trials, TNX-102 SL has demonstrated significant pain reduction and strong safety data. If approved, this therapy could become the first in a new class of fibromyalgia treatments in over 15 years, offering hope to millions of patients and their families. 💡 Learn more about Tonix’s commitment to advancing care for fibromyalgia and their plans for 2025 commercialization. 👉 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: https://lnkd.in/geK6HaZQ #fibromyalgia #chronicpain #nonopioid #clinicaltrials #fdaapproval #innovationinhealth #pharmanews #healthcare
